Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production

Ruth J. Pepper, Alan D. Salama, Margarete A. Fabre et al.|Lara D. Veeken|2008

Cited by 149